• Vorinostat: From HDAC Inhibition to Translational Insight

  2026-09-24

  Vorinostat offers a practical way to interrogate how HDAC inhibition reshapes gene expression and cell fate. This article connects its mechanism to experimental design and to emerging neuroblastoma findings, while clarifying what comparative preclinical evidence can—and cannot—tell translational researchers.

• Camostat Mesilate for Reliable Cell Assays

  2026-09-23

  Learn how to use Camostat Mesilate (SKU B2082) to investigate protease-linked signaling while interpreting cell viability and cytotoxicity results carefully. This scenario-driven guide covers assay controls, formulation, dosing, fibrosis-related readouts, and practical product-selection criteria.

• Ciprofloxacin Beyond Bacteria: A Nanomedicine Case Study

  2026-09-23

  Ciprofloxacin is best known as a fluoroquinolone antibiotic, but recent nanomedicine research shows how its physicochemical and redox-related properties can be repurposed in an ultrasound-responsive cancer platform. This article translates that finding into practical assay, formulation, and interpretation decisions without conflating antibacterial and antitumor mechanisms.

• Measuring Cancer Drug Response Beyond Viability

  2026-09-22

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent dimensions of anticancer drug response. The framework supports better assay interpretation by pairing these measurements across time rather than treating a single viability endpoint as a complete pharmacologic description.

• Afatinib in Patient-Derived Gastric Cancer Assembloids

  2026-09-22

  A translational framework for using Afatinib, also known as BIBW 2992, to distinguish tumor-intrinsic ErbB dependence from stromal modulation in patient-derived gastric cancer assembloids.

• Mc-Val-Cit-PABC-PNP ADC Linker Protocol

  2026-09-21

  Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC peptide linker for antibody-drug conjugate synthesis workflows that require a lysosomal payload-release design. It is suited to DMSO-compatible research handling, but its water and ethanol insolubility makes it unsuitable for aqueous formulations, diagnostic use, or clinical and therapeutic applications.

• NamiRNA Dual-Pathway Control in Pancreatic Cancer

  2026-09-21

  Yu et al. show that miR-200c suppresses pancreatic cancer through two mechanistically distinct routes: nuclear activation of PTPN6 transcription through an enhancer and post-transcriptional repression of CDH17. LNP delivery extended these findings into a preclinical therapeutic model, while the study design provides a framework for separating proliferation, migration, enhancer activity, and delivery effects.

• Faropenem Sodium: Translational Leverage in AMR

  2026-09-20

  Faropenem sodium offers translational researchers a distinctive way to connect penem-mediated cell wall disruption with renal transporter biology, antimicrobial susceptibility, and resistance-focused experimental design. This article examines the mechanistic evidence, practical workflow considerations, competitive positioning, and limitations that determine its value in advanced infection research.

• GDC-0941 Workflow for PI3K/Akt Assays

  2026-09-19

  Build a robust GDC-0941 workflow that connects acute PI3K/Akt pathway inhibition with proliferation, apoptosis, and resistance phenotypes. The approach also adapts lessons from pancreatic cancer research to prevent pathway assays from being overinterpreted as simple viability tests.

• Caspase-8 Fluorometric Assay Kit Workflow

  2026-09-18

  Build a sensitive caspase-8 activity workflow for apoptosis, combination-therapy, and cell-death studies. This guide combines IETD-AFC fluorescence with treatment controls and orthogonal validation to distinguish pathway activation from nonspecific cell loss.

• ZIF8 Nanotheranostics for Ultrasound-Guided TNBC

  2026-09-18

  Li et al. developed FA-PEG@ZIF8@CIP, a folic acid- and polyethylene glycol-functionalized ZIF-8 nanoplatform that combines ultrasound imaging, sonodynamic therapy, chemotherapy, and immune activation for triple-negative breast cancer. The study links ultrasound-enhanced reactive oxygen species production with immunogenic cell death and increased cytotoxic T-cell infiltration, while also identifying practical limitations for translating the system beyond its preclinical model.

• 11β-HSD1, Notch, and NK Cells in Liver Fibrosis

  2026-09-17

  A 2025 mouse study shows that inhibiting 11β-HSD1 reduces thioacetamide-induced liver fibrosis through coordinated suppression of Notch signaling and enhancement of natural killer cell responses. The findings connect intrahepatic cortisol regulation with hepatic stellate cell activity and immune-mediated clearance, while also defining important limits for translation to MASLD and MASH research.

• Carbapenemase Transmission in Enterobacter cloacae

  2026-09-17

  A 2025 BMC Microbiology study integrated gene localization, antimicrobial susceptibility, conjugation, mobile-element analysis, and strain typing to investigate carbapenem-resistant Enterobacter cloacae from eight teaching hospitals in Guangdong. Its central finding was that blaNDM-1 was frequently plasmid-associated and highly transferable, linking multidrug resistance with both horizontal and clonal dissemination risks.

• IWR-1-endo: Wnt Signaling Inhibitor Workflows

  2026-09-16

  IWR-1-endo enables controlled pathway perturbation across colorectal cancer, stem-cell, regeneration, and exploratory cardiac assays. This practical guide links Axin-complex stabilization to reproducible dosing, morphology profiling, β-catenin readouts, and troubleshooting.

• Meropenem Workflows for Resistance Research

  2026-09-16

  Build reproducible Meropenem assays for susceptibility testing, resistance dynamics, and Gram-negative infection models. This workflow-centered guide connects PBP biology with plasmid-transmission analysis, formulation comparisons, and septicemia treatment research while keeping exploratory findings separate from clinical interpretation.

8309 records 1/554 page Next 12345 下5页 Last page